NEW YORK (GenomeWeb News) – XDx said this week that health insurer Cigna has issued a positive coverage decision for XDx's AlloMap Molecular Expression Testing for potential heart transplant rejection.

The policy, which took effect immediately, applies to about 13.8 million lives covered by Cigna. Barry Kane, senior director of finance and reimbursement at XDx, said the firm is "particularly pleased" that Cigna is formally covering AlloMap for patients six months to five years post-heart transplant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.